Design of a multicenter randomized controlled trial of a post‐discharge suicide prevention intervention for high‐risk psychiatric inpatients: The Veterans Coordinated Community Care Study

Lauren M. Weinstock,Todd M. Bishop,Mark S. Bauer,Jeffrey Benware,Robert M. Bossarte,John Bradley,Steven K. Dobscha,Jessica Gibbs,Sarah M. Gildea,Hannah Graves,Gretchen Haas,Samuel House,Chris J. Kennedy,Sara J. Landes,Howard Liu,Alex Luedtke,Brian P. Marx,Aletha Miller,Matthew K. Nock,Richard R. Owen,Wilfred R. Pigeon,Nancy A. Sampson,Alejandro Santiago‐Colon,Geetha Shivakumar,Snezana Urosevic,Ronald C. Kessler
DOI: https://doi.org/10.1002/mpr.70003
2024-10-02
International Journal of Methods in Psychiatric Research
Abstract:Abstract Background The period after psychiatric hospital discharge is one of elevated risk for suicide‐related behaviors (SRBs). Post‐discharge clinical outreach, although potentially effective in preventing SRBs, would be more cost‐effective if targeted at high‐risk patients. To this end, a machine learning model was developed to predict post‐discharge suicides among Veterans Health Administration (VHA) psychiatric inpatients and target a high‐risk preventive intervention. Methods The Veterans Coordinated Community Care (3C) Study is a multicenter randomized controlled trial using this model to identify high‐risk VHA psychiatric inpatients ( n = 850) randomized with equal allocation to either the Coping Long Term with Active Suicide Program (CLASP) post‐discharge clinical outreach intervention or treatment‐as‐usual (TAU). The primary outcome is SRBs over a 6‐month follow‐up. We will estimate average treatment effects adjusted for loss to follow‐up and investigate the possibility of heterogeneity of treatment effects. Results Recruitment is underway and will end September 2024. Six‐month follow‐up will end and analysis will begin in Summer 2025. Conclusion Results will provide information about the effectiveness of CLASP versus TAU in reducing post‐discharge SRBs and provide guidance to VHA clinicians and policymakers about the implications of targeted use of CLASP among high‐risk psychiatric inpatients in the months after hospital discharge. Clinical trials registration ClinicalTrials.Gov identifier: NCT05272176 ( https://www.clinicaltrials.gov/ct2/show/NCT05272176 ).
psychiatry
What problem does this paper attempt to address?